Recurrent KRAS codon 146 mutations in human colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Somatic mutations in RAS genes (HRAS, KRAS, NRAS) are key drivers of human cancer.
• Previous research focused on mutations in codons 12, 13, and 61.
• The role of other conserved residues in RAS gene function and oncogenesis remains to be fully elucidated.

Purpose of the Study:

• To identify and characterize novel recurrent somatic mutations in RAS genes.
• To investigate the frequency and potential contribution of mutations at alanine 146 in colorectal cancer.
• To explore the presence of alanine 146 mutations in other cancer types.

Main Methods:

• Somatic mutation screening of KRAS and NRAS genes.
• Analysis of patient-derived colorectal cancer samples from Hong Kong and the United States.
• Examination of colorectal cancer cell lines, including the NCI-60 panel.
• Screening of lung cancer and leukemia cell lines for alanine 146 mutations.

Main Results:

• Recurrent somatic missense mutations at alanine 146 (A146) were identified in KRAS.
• KRAS A146 mutations were found in 4% of colorectal cancers and 5% of colorectal cancer cell lines.
• These mutations were not detected in lung adenocarcinomas or large cell carcinomas.
• KRAS A146 mutations were identified in an acute myeloid leukemia cell line, and NRAS A146 mutations in a B-cell acute lymphoblastic leukemia line.

Conclusions:

• Alanine 146 mutations in KRAS represent a significant and previously underappreciated contributor to colorectal cancer.
• The frequency of KRAS A146 mutations may be comparable to or greater than that of codon 61 mutations in colorectal cancer.
• The presence of A146 mutations in leukemia cell lines suggests their broader role in oncogenesis beyond colorectal cancer and KRAS.